Chirality-Controlled Carbon Nanotubes Fabricated by Self-Assembly of Graphene Nanoribbons

We demonstrate by molecular dynamics simulations that carbon nanotubes can activate and guide on their surfaces the fabrication of single-walled carbon nanotubes by self-assembly of edge-unpassivated twisted graphene nanoribbons. Temperature is a governing factor, which mainly controls the self-assembly process. Three types of stable configurations exist due to the self-assembly of twisted graphene nanoribbons at constant temperatures, i.e., a helical structure, a self-assembled carbon nanotube, and a nearly straight graphene strip, on a basal carbon nanotube. Raising the temperature gradually, the helical structure can spontaneously switch to a single-walled carbon nanotube or a nearly straight graphene strip. The straight graphene strip can further turn into a self-assembled carbon nanotube through annealing technique. Furthermore, the chirality of the self-assembled carbon nanotube can be predicted by the width of the twisted graphene nanoribbon and the radius of the basal carbon nanotube. Our finding should be useful for the design of nanodevices with chirality-controlled nanotubes

Image2_Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.TIF

Body-protective compound (BPC) 157 demonstrates protective effects against damage to various organs and tissues. For future clinical applications, we had previously established a solid-phase synthesis process for BPC157, verified its biological activity in different wound models, and completed preclinical safety evaluations. This study aimed to investigate the pharmacokinetics, excretion, metabolism, and distribution profiles of BPC157. After a single intravenous (IV) administration, single intramuscular (IM) administrations at three doses in successive increments along with repeated IM administrations, the elimination half-life (t1/2) of prototype BPC157 was less than 30 min, and BPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses. The mean absolute bioavailability of BPC157 following IM injection was approximately 14%–19% in rats and 45%–51% in beagle dogs. Using [3H]-labeled BPC157 and radioactivity examination, we proved that the main excretory pathways of BPC157 involved urine and bile. [3H]BPC157 was rapidly metabolized into a variety of small peptide fragments in vivo, thus forming single amino acids that entered normal amino acid metabolism and excretion pathways. In conclusion, this study provides the first analysis of the pharmacokinetics of BPC157, which will be helpful for its translation in the clinic.</p

Image1_Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.TIF

Body-protective compound (BPC) 157 demonstrates protective effects against damage to various organs and tissues. For future clinical applications, we had previously established a solid-phase synthesis process for BPC157, verified its biological activity in different wound models, and completed preclinical safety evaluations. This study aimed to investigate the pharmacokinetics, excretion, metabolism, and distribution profiles of BPC157. After a single intravenous (IV) administration, single intramuscular (IM) administrations at three doses in successive increments along with repeated IM administrations, the elimination half-life (t1/2) of prototype BPC157 was less than 30 min, and BPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses. The mean absolute bioavailability of BPC157 following IM injection was approximately 14%–19% in rats and 45%–51% in beagle dogs. Using [3H]-labeled BPC157 and radioactivity examination, we proved that the main excretory pathways of BPC157 involved urine and bile. [3H]BPC157 was rapidly metabolized into a variety of small peptide fragments in vivo, thus forming single amino acids that entered normal amino acid metabolism and excretion pathways. In conclusion, this study provides the first analysis of the pharmacokinetics of BPC157, which will be helpful for its translation in the clinic.</p

sj-docx-1-wso-10.1177_17474930231205221 – Supplemental material for The frequency of imaging markers adjusted for time since symptom onset in intracerebral hemorrhage: A novel predictor for hematoma expansion

Supplemental material, sj-docx-1-wso-10.1177_17474930231205221 for The frequency of imaging markers adjusted for time since symptom onset in intracerebral hemorrhage: A novel predictor for hematoma expansion by Lei Song, Jun Cheng, Cun Zhang, Hang Zhou, Wenmin Guo, Yu Ye, Rujia Wang, Hui Xiong, Ji Zhang, Ren Ke, Dongfang Tang, Yufei Fu, Zhibing He, Liwei Zou, Longsheng Wang, Lianghong Kuang, Xiaoming Qiu, Tingting Guo and Yongqiang Yu in International Journal of Stroke</p